S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenx SE stock logo
ARGX
argenx
$358.41
-2.1%
$388.25
$327.73
$550.76
$21.25B0.65319,265 shs261,754 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$56.16
+1.1%
$73.51
$37.55
$91.10
$4.77B1.761.85 million shs1.74 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$132.54
-0.5%
$136.16
$89.04
$148.37
$13.26B0.25830,496 shs549,307 shs
Qiagen stock logo
QGEN
Qiagen
$39.49
+0.7%
$42.83
$34.74
$47.70
$8.95B0.41822,385 shs951,915 shs
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$178.75
$176.25
$108.82
$189.99
$10.93B0.13572,759 shsN/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenx SE stock logo
ARGX
argenx
-2.13%-5.59%-0.27%-2.31%-6.20%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+1.08%-10.73%-21.96%-9.40%+5.01%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
-0.52%-2.49%-5.91%-3.52%+26.39%
Qiagen stock logo
QGEN
Qiagen
+0.66%-4.08%-10.27%-15.12%-15.72%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenx SE stock logo
ARGX
argenx
3.74 of 5 stars
4.45.00.00.03.21.70.6
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.4307 of 5 stars
4.21.00.00.02.02.50.6
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.3933 of 5 stars
2.44.00.02.92.62.53.1
Qiagen stock logo
QGEN
Qiagen
4.4176 of 5 stars
3.33.00.04.51.41.72.5
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenx SE stock logo
ARGX
argenx
2.71
Moderate Buy$528.1647.36% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.38
Hold$76.2935.84% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.73
Moderate Buy$139.675.38% Upside
Qiagen stock logo
QGEN
Qiagen
2.63
Moderate Buy$51.6930.89% Upside
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/A

Current Analyst Ratings

Latest QGEN, CRSP, NBIX, XLRN, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
argenx SE stock logo
ARGX
argenx
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$521.00
4/18/2024
argenx SE stock logo
ARGX
argenx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$451.00
4/18/2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$88.00 ➝ $89.00
4/17/2024
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$147.00
4/11/2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
4/10/2024
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$155.00
3/27/2024
argenx SE stock logo
ARGX
argenx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$451.00
3/26/2024
argenx SE stock logo
ARGX
argenx
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$402.00 ➝ $408.00
3/22/2024
argenx SE stock logo
ARGX
argenx
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$471.00
3/20/2024
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$148.00 ➝ $158.00
3/6/2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $99.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenx SE stock logo
ARGX
argenx
$1.27B16.75N/AN/A$69.22 per share5.18
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$371.21M12.84N/AN/A$23.70 per share2.37
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$1.89B6.99$2.57 per share51.66$22.72 per share5.83
Qiagen stock logo
QGEN
Qiagen
$1.97B4.59$3.14 per share12.57$16.69 per share2.37
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$92.52M118.15N/AN/A$11.74 per share15.23

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenx SE stock logo
ARGX
argenx
-$295.05M-$5.14N/A108.61N/A-23.26%-16.97%-15.26%5/2/2024 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$153.61M-$1.96N/AN/AN/AN/A-8.09%-6.73%5/13/2024 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$249.70M$2.4254.7721.27N/A13.23%12.85%9.02%5/1/2024 (Confirmed)
Qiagen stock logo
QGEN
Qiagen
$341.30M$1.5126.1017.473.3117.37%12.99%7.74%4/29/2024 (Confirmed)
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/A

Latest QGEN, CRSP, NBIX, XLRN, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$1.04N/A-$1.04N/AN/AN/A  
4/29/2024N/A
Qiagen stock logo
QGEN
Qiagen
$0.44N/A-$0.44N/AN/AN/A  
2/29/202412/31/2023
argenx SE stock logo
ARGX
argenx
-$1.23-$1.68-$0.45-$1.68$378.60 million$417.84 million    
2/21/2024Q4 2023
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$0.15$1.10+$0.95$1.10$148.72 million$201.20 million
2/7/2024Q4 2023
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$1.13$1.44+$0.31$1.44$518.52 million$515.20 million      
2/6/2024Q4 23
Qiagen stock logo
QGEN
Qiagen
$0.55$0.55N/A$0.68$500.77 million$509.00 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenx SE stock logo
ARGX
argenx
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
N/AN/AN/AN/AN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/AN/A

Latest QGEN, CRSP, NBIX, XLRN, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/22/2024
Qiagen stock logo
QGEN
Qiagen
--$1.31961/30/20241/31/20241/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenx SE stock logo
ARGX
argenx
N/A
9.75
9.01
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
17.54
17.54
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
2.45
2.40
Qiagen stock logo
QGEN
Qiagen
0.24
1.99
1.62
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/A
12.14
12.14

Ownership

Institutional Ownership

CompanyInstitutional Ownership
argenx SE stock logo
ARGX
argenx
60.32%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Qiagen stock logo
QGEN
Qiagen
70.00%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
90.35%

Insider Ownership

CompanyInsider Ownership
argenx SE stock logo
ARGX
argenx
2.43%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.40%
Qiagen stock logo
QGEN
Qiagen
9.00%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
1.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
argenx SE stock logo
ARGX
argenx
1,14859.30 million57.86 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
47384.88 million81.40 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
1,40099.51 million95.13 millionOptionable
Qiagen stock logo
QGEN
Qiagen
5,967228.20 million207.67 millionOptionable
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
31261.16 million60.12 millionOptionable

QGEN, CRSP, NBIX, XLRN, and ARGX Headlines

SourceHeadline
ORBIMED CAPITAL GP II LLCs Net WorthORBIMED CAPITAL GP II LLC's Net Worth
benzinga.com - February 27 at 3:47 PM
XLRN Historical DataXLRN Historical Data
investing.com - October 20 at 10:08 AM
MSD eyes March FDA decision on PAH drug sotaterceptMSD eyes March FDA decision on PAH drug sotatercept
pharmaphorum.com - October 16 at 12:20 AM
Brexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyBrexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley
thestreet.com - April 15 at 8:35 AM
Astellas Pharma IncAstellas Pharma Inc
reuters.com - March 17 at 6:17 AM
HempStreet partners with MGC Pharma launches ArtemiCHempStreet partners with MGC Pharma launches ArtemiC
health.economictimes.indiatimes.com - January 30 at 11:12 PM
Acceleron Corp Becomes a Digital Correspondent BankAcceleron Corp Becomes a Digital Correspondent Bank
finance.yahoo.com - December 14 at 8:40 AM
Pharma Contract Sales Market Report 2022-2032Pharma Contract Sales Market Report 2022-2032
finance.yahoo.com - November 30 at 8:26 PM
Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugsMerck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs
reuters.com - November 21 at 12:55 PM
Pharmalittle: BIO CEO resigns amid board disagreements; Pfizer exec denies allegations over EU Covid-vaccine dealPharmalittle: BIO CEO resigns amid board disagreements; Pfizer exec denies allegations over EU Covid-vaccine deal
statnews.com - October 11 at 10:48 AM
Boost for Merck as Acceleron drug clears key phase 3 hurdleBoost for Merck as Acceleron drug clears key phase 3 hurdle
pharmaphorum.com - October 11 at 12:29 AM
Centre Piece Of Mercks $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular TrialCentre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular Trial
msn.com - October 10 at 2:29 PM
Merck touts positive results on key drug from $11.5 billion Acceleron mergerMerck touts positive results on key drug from $11.5 billion Acceleron merger
statnews.com - October 10 at 8:14 AM
Liquidia slumps as United, MannKind get FDA nod for rival therapyLiquidia slumps as United, MannKind get FDA nod for rival therapy
seekingalpha.com - May 23 at 4:11 PM
Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyoutMerck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout
endpts.com - March 31 at 9:00 AM
19 Charts to Calm Your Recession Fears19 Charts to Calm Your Recession Fears
thestreet.com - January 20 at 10:48 PM
XLRN May 2022 140.000 putXLRN May 2022 140.000 put
finance.yahoo.com - December 22 at 10:04 PM
Merck Sells $8 Billion of Bonds to Fund Acceleron AcquisitionMerck Sells $8 Billion of Bonds to Fund Acceleron Acquisition
bloombergquint.com - December 7 at 7:55 PM
Merck Completes Acquisition of Acceleron PharmaMerck Completes Acquisition of Acceleron Pharma
smarteranalyst.com - November 23 at 9:33 AM
Merck Closes Biggest Biotech Deal of the YearMerck Closes Biggest Biotech Deal of the Year
finance.yahoo.com - November 22 at 2:09 PM
Merck announces completion of Acceleron Pharma acquisitionMerck announces completion of Acceleron Pharma acquisition
seekingalpha.com - November 22 at 7:52 AM
Mercks (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN)Merck's (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN)
nasdaq.com - November 21 at 8:45 AM
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
us.acrofan.com - November 19 at 6:17 PM
Market cap of Acceleron Pharma Inc. [XLRN] reaches 10.99B – now what?Market cap of Acceleron Pharma Inc. [XLRN] reaches 10.99B – now what?
dbtnews.com - November 18 at 10:01 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

argenx logo

argenx

NASDAQ:ARGX
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
CRISPR Therapeutics logo

CRISPR Therapeutics

NASDAQ:CRSP
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Neurocrine Biosciences logo

Neurocrine Biosciences

NASDAQ:NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Qiagen logo

Qiagen

NYSE:QGEN
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Acceleron Pharma logo

Acceleron Pharma

NASDAQ:XLRN
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.